These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37070539)

  • 1. Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV.
    Griffin DWJ; Pai Mangalore R; Hoy JF; McMahon JH
    AIDS; 2023 Jul; 37(9):1345-1360. PubMed ID: 37070539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2.
    Pourcher V; Belin L; Soulie C; Rosenzwajg M; Marot S; Lacombe K; Valin N; Pialoux G; Calin R; Palacios C; Malet I; Zafilaza K; Tubiana R; Valantin MA; Klatzmann D; Calvez V; Simon-Tillaux N; Marcelin AG
    AIDS; 2022 Sep; 36(11):1545-1552. PubMed ID: 35730380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired antibody response to COVID-19 vaccination in advanced HIV infection.
    Hassold N; Brichler S; Ouedraogo E; Leclerc D; Carroue S; Gater Y; Alloui C; Carbonnelle E; Bouchaud O; Mechai F; Cordel H; Delagreverie H
    AIDS; 2022 Mar; 36(4):F1-F5. PubMed ID: 35013085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
    Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
    Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus.
    Casado-Fernández G; Cantón J; Nasarre L; Ramos-Martín F; Manzanares M; Sánchez-Menéndez C; Fuertes D; Mateos E; Murciano-Antón MA; Pérez-Olmeda M; Cervero M; Torres M; Rodríguez-Rosado R; Coiras M
    Front Immunol; 2024; 15():1362621. PubMed ID: 38812512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study-ANRS0001s COV-POPART.
    Loubet P; Lelievre JD; François A; Botelho-Nevers E; Chidiac C; Chirio D; Dubee V; Dussol B; Galtier F; Hessamfar M; Hodaj E; Jaffuel S; Lacombe K; Laine F; Lefebvre M; Maakaroun-Vermesse Z; Makinson A; Portefaix A; Pourcher V; Rey D; Zucman D; Longobardi J; Bertheau M; Tartour E; de Lamballerie X; Launay O; Wittkop L;
    Int J Infect Dis; 2024 Sep; 146():107110. PubMed ID: 38825164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
    PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1.
    Chammartin F; Griessbach A; Kusejko K; Audigé A; Epp S; Stoeckle MP; Eichenberger AL; Amstutz A; Schoenenberger CM; Hasse B; Braun DL; Rauch A; Trkola A; Briel M; Bucher HC; Günthard HF; Speich B; Abela IA;
    AIDS; 2024 Feb; 38(2):217-222. PubMed ID: 37830908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study.
    Li J; Nie L; Guo C; Deng Y; Guo Q; Pang C; Xin R; Li J; Lu H; Huang C
    J Med Virol; 2023 Dec; 95(12):e29334. PubMed ID: 38140842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV.
    Liu WD; Lin MS; Sun HY; Shih MC; Chuang YC; Huang YS; Lin KY; Li GC; Wu PY; Chen LY; Liu WC; Su YC; He PC; Chen YT; Lin CY; Cheng YC; Yao Y; Yeh YC; Liu CC; Pan MY; Luo YZ; Chang HY; Wang JT; Sheng WH; Hsieh SM; Chang SY; Hung CC
    J Microbiol Immunol Infect; 2024 Aug; 57(4):554-563. PubMed ID: 38429206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
    Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F
    Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States.
    Coburn SB; Humes E; Lang R; Stewart C; Hogan BC; Gebo KA; Napravnik S; Edwards JK; Browne LE; Park LS; Justice AC; Gordon KS; Horberg MA; Certa JM; Watson E; Jefferson CR; Silverberg MJ; Skarbinski J; Leyden WA; Williams CF; Althoff KN;
    JAMA Netw Open; 2022 Jun; 5(6):e2215934. PubMed ID: 35671054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV.
    Mauas R; Urueña A; Cecchini D; Strada ML; Arietti S; Cassetti I; Nogueira NF; Salazar AS; Rodriguez VJ; Jones DL; Alcaide ML
    AIDS; 2023 May; 37(6):941-946. PubMed ID: 36728228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.
    Netto LC; Ibrahim KY; Picone CM; Alves APPS; Aniceto EV; Santiago MR; Parmejani PSS; Aikawa NE; Medeiros-Ribeiro AC; Pasoto SG; Yuki EFN; Saad CGS; Pedrosa T; Lara AN; Ceneviva C; Bonfa E; Kallas EG; Avelino-Silva VI
    Lancet HIV; 2022 May; 9(5):e323-e331. PubMed ID: 35338835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.
    Benet S; Blanch-Lombarte O; Ainsua-Enrich E; Pedreño-Lopez N; Muñoz-Basagoiti J; Raïch-Regué D; Perez-Zsolt D; Peña R; Jiménez E; Rodríguez de la Concepción ML; Ávila C; Cedeño S; Escribà T; Romero-Martín L; Alarcón-Soto Y; Rodriguez-Lozano GF; Miranda C; González S; Bailón L; Blanco J; Massanella M; Brander C; Clotet B; Paredes R; Esteve M; Izquierdo-Useros N; Carrillo J; Prado JG; Moltó J; Mothe B
    J Infect Dis; 2022 Nov; 226(11):1913-1923. PubMed ID: 36200261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada.
    Costiniuk CT; Singer J; Lee T; Galipeau Y; McCluskie PS; Arnold C; Langlois MA; Needham J; Jenabian MA; Burchell AN; Samji H; Chambers C; Walmsley S; Ostrowski M; Kovacs C; Tan DHS; Harris M; Hull M; Brumme ZL; Lapointe HR; Brockman MA; Margolese S; Mandarino E; Samarani S; Vulesevic B; Lebouché B; Angel JB; Routy JP; Cooper CL; Anis AH;
    AIDS; 2023 Oct; 37(12):F25-F35. PubMed ID: 37534695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV.
    Motta E; Camacho LAB; Cunha M; de Filippis AMB; Lima SMB; Costa M; Pedro L; Cardoso SW; Cortes FH; Giacoia-Gripp CBW; Morata M; Nazer S; Moreira RI; de Oliveira Souza MC; Mendes YS; Souza Azevedo A; Dos Santos Alvez N; Grinsztejn B; Coelho LE
    AIDS; 2023 Dec; 37(15):2319-2329. PubMed ID: 37650759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine.
    Wong NS; Wong BCK; Chan JMC; Wong KH; Tsang OTY; Mok CKP; Hui DSC; Lee SS; Chan DPC
    AIDS; 2022 Jul; 36(9):1255-1264. PubMed ID: 35466962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of HIV on COVID-19 vaccine responses.
    Levy I; Rahav G
    Curr Opin HIV AIDS; 2023 May; 18(3):135-141. PubMed ID: 36943427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
    Frater J; Ewer KJ; Ogbe A; Pace M; Adele S; Adland E; Alagaratnam J; Aley PK; Ali M; Ansari MA; Bara A; Bittaye M; Broadhead S; Brown A; Brown H; Cappuccini F; Cooney E; Dejnirattisai W; Dold C; Fairhead C; Fok H; Folegatti PM; Fowler J; Gibbs C; Goodman AL; Jenkin D; Jones M; Makinson R; Marchevsky NG; Mujadidi YF; Nguyen H; Parolini L; Petersen C; Plested E; Pollock KM; Ramasamy MN; Rhead S; Robinson H; Robinson N; Rongkard P; Ryan F; Serrano S; Tipoe T; Voysey M; Waters A; Zacharopoulou P; Barnes E; Dunachie S; Goulder P; Klenerman P; Screaton GR; Winston A; Hill AVS; Gilbert SC; Pollard AJ; Fidler S; Fox J; Lambe T;
    Lancet HIV; 2021 Aug; 8(8):e474-e485. PubMed ID: 34153264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.